Results of static analyzes for selected drugs with an established position in the treatment of cardiovascular diseases Review article

Main Article Content

Paweł Balsam
Marcin Grabowski

Abstract

Currently, in the therapy of cardiovascular diseases, numerous drugs are used to improve the prognosis of patients. These include angiotensin-converting enzyme inhibitors (ACE-I), sartans or statins. At the same time, due to the huge number of patients using these drugs, there are reports of possible side-effects. This article presents the status of possible additional effects/ side effects for ACE-I, sartans, statin and hydrochlorothiazide.

Article Details

How to Cite
Balsam , P., & Grabowski , M. (2019). Results of static analyzes for selected drugs with an established position in the treatment of cardiovascular diseases. Medycyna Faktow (J EBM), 12(2(43), 103-108. https://doi.org/10.24292/01.MF.0219.3
Section
Articles

References

1. Clere N., Corre I., Faure S. et al.: Deficiency or blockade of angiotensin II type 2 receptor delays tumorigenesis by inhibiting malignant cell proliferation and angiogenesis. Int. J. Cancer 2010; 127(10): 2279-2291.
2. Hicks B.M., Filion K.B., Yin H. et al.: Angiotensin converting enzyme inhibitors and risk of lung cancer: population based cohort study. BMJ 2018; 363: k4209.
3. Hanif K., Bid H.K., Konwar R.: Reinventing the ACE inhibitors: some old and new implications of ACE inhibition. Hypertens. Res. 2010; 33(1): 11-21.
4. Cronin-Fenton D.: Angiotensin converting enzyme inhibitors and lung cancer. Any extra risk must be balanced against the mortality benefits of ACEI use. BMJ 2018; 363: k4337.
5. Sipahi I., Debanne S.M., Rowland D.Y. et al.: Angiotensin-receptor blockade and risk of cancer: meta-analysis of randomised controlled trials. Lancet Oncol. 2010; 11(7): 627-636.
6. Volpe M., Azizi M., Danser A.H. et al.: Twisting arms to angiotensin receptor blockers/antagonists: the turn of cancer. Eur. Heart J. 2011; 32(1): 19-22.
7. Pfeffer M.A., Swedberg K., Granger C.B. et al.: Effects of candesartan on mortality and morbidity in patients with chronic heart failure: the CHARM-Overall programme. Lancet 2003; 362(9386): 759-766.
8. ARB Trialists Collaboration: Effects of telmisartan, irbesartan, valsartan, candesartan, and losartan on cancers in 15 trials enrolling 138,769 individuals. J. Hypertens. 2011; 29(4): 623-635.
9. Bangalore S., Kumar S., Wetterslev J. et al.: Angiotensin receptor blockers and risk of myocardial infarction: meta-analyses and trial sequential analyses of 147 020 patients from randomised trials. BMJ 2011; 342: d2234.
10. Yoon C., Yang H.S., Jeon I. et al.: Use of angiotensin-converting-enzyme inhibitors or angiotensin-receptor blockers and cancer risk: a meta- analysis of observational studies. CMAJ 2011; 183(14): E1073-1084.
11. Pasternak B., Svanström H., Callréus T. et al.: Use of angiotensin receptor blockers and the risk of cancer. Circulation 2011; 123(16): 1729-1736.
12. Huang C.C., Chan W.L., Chen Y.C. et al.: Angiotensin II receptor blockers and risk of cancer in patients with systemic hypertension. Am. J. Cardiol. 2011; 107(7): 1028-1033.
13. Catapano A.L., Graham I., De Backer G. et al.: 2016 ESC/EAS Guidelines for the Management of Dyslipidaemias. Kardiol. Pol. 2016; 74(11): 1234-1318.
14. Williams B., Mancia G., Spiering W. et al.: 2018 Practice Guidelines for the management of arterial hypertension of the European Society of Hypertension and the European Society of Cardiology: ESH/ESC Task Force for the Management of Arterial Hypertension. J. Hypertens. 2018; 36(12): 2284-2309.
15. Pedersen S.A., Gaist D., Schmidt S.A.J. et al.: Hydrochlorothiazide use and risk of nonmelanoma skin cancer: A nationwide case-control study from Denmark. J. Am. Acad. Dermatol. 2018; 78(4): 673-681e9.